Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
20s Proteasome - Overview
20s Proteasome - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
20s Proteasome - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
20s Proteasome - Companies Involved in Therapeutics Development
Amgen Inc
Bristol-Myers Squibb Co
Centrax Intertiol Inc
HuniLife Biotechnology Inc
Lodo Therapeutics Corp
20s Proteasome - Drug Profiles
carfilzomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-13608 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuL-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
marizomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oprozomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTSV-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit 20S Proteasome for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 20s Proteasome for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TIR-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
20s Proteasome - Dormant Products
20s Proteasome - Product Development Milestones
Featured News & Press Releases
Nov 12, 2020: CHMP adopts a positive opinion recommending a change to the terms of the marketing authorisation for Kyprolis
Aug 20, 2020: FDA approves new KYPROLIS (carfilzomib) combition regimen with DARZALEX (daratumumab) and Dexamethasone in both once- and twice-weekly dosing regimens
May 14, 2020: Oncolytics Biotech announces publication of abstract on Kyprolis at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
May 13, 2020: Amgen presents update on KYPROLIS at ASCO 2020
May 05, 2020: KYPROLIS (carfilzomib) patents upheld against generic manufacturer
Dec 11, 2019: Amgen reports positive data in multiple myeloma study
Dec 02, 2019: Amgen announces data to be presented on KYPROLIS (carfilzomib) at ASH 2019
Sep 13, 2019: Amgen announces phase 3 CANDOR study combining KYPROLIS (carfilzomib) and DARZALEX (daratumumab) meets primary endpoint of progression-free survival
Sep 12, 2019: Amgen highlights new data From KYPROLIS (carfilzomib) and Oncology Pipeline At IMW 2019
Aug 19, 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events
Jun 19, 2019: Early Indications of potential Heart Conditions Using Carfilzomib in Multiple Myeloma
Jun 13, 2019: Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy
Apr 25, 2019: Amgen agree to pay a total of nearly $24.75 million to resolve allegations that it paid kickbacks through copay assistance foundations
Mar 19, 2019: ONO submits supplemental application of Kyprolis for intravenous injection, a proteasome inhibitor, for additiol dosage and administration for the treatment of relapsed or refractory multiple myeloma in Japan
Nov 01, 2018: Amgen to present new data on Carfilzomib at ASH 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Amgen Inc, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Centrax International Inc, H2 2020
Pipeline by HuniLife Biotechnology Inc, H2 2020
Pipeline by Lodo Therapeutics Corp, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020